These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson's Disease Research. Jong T; Gehrlein A; Sidransky E; Jagasia R; Chen Y J Parkinsons Dis; 2024; 14(1):65-78. PubMed ID: 38251062 [TBL] [Abstract][Full Text] [Related]
8. Activation and Purification of ß-Glucocerebrosidase by Exploiting its Transporter LIMP-2 - Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease. Dobert JP; Bub S; Mächtel R; Januliene D; Steger L; Regensburger M; Wilfling S; Chen JX; Dejung M; Plötz S; Hehr U; Moeller A; Arnold P; Zunke F Adv Sci (Weinh); 2024 Jul; 11(25):e2401641. PubMed ID: 38666485 [TBL] [Abstract][Full Text] [Related]
9. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Menozzi E; Toffoli M; Schapira AHV Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432 [TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease. Cyske Z; Gaffke L; Rintz E; Wiśniewska K; Węgrzyn G; Pierzynowska K Neurochem Int; 2024 Sep; 178():105774. PubMed ID: 38797393 [TBL] [Abstract][Full Text] [Related]
11. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596 [TBL] [Abstract][Full Text] [Related]
12. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179 [TBL] [Abstract][Full Text] [Related]
13. Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease. Marano M; Zizzo C; Malaguti MC; Bacchin R; Cavallieri F; De Micco R; Spagnolo F; Bentivoglio AR; Schirinzi T; Bovenzi R; Ramat S; Erro R; Sorrentino C; Sucapane P; Pilotto A; Lupini A; Magliozzi A; Di Vico I; Carecchio M; Bonato G; Cilia R; Colucci F; Tamma F; Caputo E; Mostile G; Arabia G; Modugno N; Zibetti M; Ceravolo MG; Tambasco N; Cossu G; Valzania F; Manganotti P; Di Lazzaro V; Zappia M; Fabbrini G; Tinazzi M; Tessitore A; Duro G; Di Fonzo A Parkinsonism Relat Disord; 2024 Jul; 124():107023. PubMed ID: 38843618 [TBL] [Abstract][Full Text] [Related]
14. The relationship between glucocerebrosidase mutations and Parkinson disease. Migdalska-Richards A; Schapira AH J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875 [TBL] [Abstract][Full Text] [Related]
15. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312 [TBL] [Abstract][Full Text] [Related]
16. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. Goldin E; Zheng W; Motabar O; Southall N; Choi JH; Marugan J; Austin CP; Sidransky E PLoS One; 2012; 7(1):e29861. PubMed ID: 22272254 [TBL] [Abstract][Full Text] [Related]
17. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease. Menozzi E; Schapira AHV CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746 [TBL] [Abstract][Full Text] [Related]
18. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease. Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292 [TBL] [Abstract][Full Text] [Related]
20. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease. Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]